India Biologics Market Size, Share, Growth, Trends and Forecast 2035
The India Biologics Market is emerging as an important segment of the Indian healthcare and biotechnology industry. According to Market Research Future, the market was valued at USD 30.81 billion in 2024 and is projected to reach USD 166.91 billion by 2035, expanding at a CAGR of approximately 16.6% during the 2025–2035 forecast period.
The growth of biologics in India is supported by the increasing prevalence of chronic diseases, rising healthcare expenditure, growing demand for advanced therapies, and increasing investment in biotechnology research. Biologics such as monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies are becoming increasingly important in modern healthcare.
Monoclonal antibodies represent a major product segment, supported by their applications in oncology and autoimmune disorders. Vaccines are also experiencing strong growth because of increasing emphasis on preventive healthcare and immunization.
India is additionally strengthening its position as a biopharmaceutical manufacturing hub. Domestic capabilities, cost advantages, biosimilar development, and improving manufacturing infrastructure are creating opportunities for both local and international companies.
Government initiatives supporting biotechnology research and innovation are further encouraging investment in biologics. Growing collaboration between pharmaceutical companies, research institutions, and biotechnology organizations is expected to accelerate product development.
Overall, technological advancement, expanding manufacturing capacity, rising healthcare demand, and increasing adoption of affordable biologics are expected to support substantial growth in India's biologics industry through 2035.